Publications

BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies.

PubMed.gov

Mitochondrial priming of chronic lymphocytic leukemia patients associates Bcl-xL dependence with alvocidib response.

PubMed.gov

Mcl-1 dependence predicts response to vorinostat and gemtuzumab ozogamicin in acute myeloid leukemia.

PubMed.gov

Discriminating response to cytarabine-based treatment of acute myelogenous leukemia.

PubMed.gov

Hydroxyquinoline-derived compounds and analoguing of selective Mcl-1 inhibitors using a functional biomarker.

PubMed.gov

Mcl-1 mediates TWEAK/Fn14-induced non-small cell lung cancer survival and therapeutic response.

PubMed.gov

Effects of Bcl-2 levels on Fas signaling-induced caspase-3 activation: molecular genetic tests of computational model predictions.

PubMed.gov

Eutropics is awarded a MassVentures START program award. The MassVentures START program provides funding to Massachusetts-based companies that are commercializing technologies developed under SBIR and STTR contracts.

Mass-Ventures.com